PainReform (PRFX) Competitors $1.42 -0.03 (-2.07%) Closing price 08/14/2025 03:46 PM EasternExtended Trading$1.40 -0.02 (-1.34%) As of 08/14/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. PHXM, IBIO, SNSE, BCDA, IMCC, BIVI, BFRI, RNAZ, AIMD, and XFORShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include PHAXIAM Therapeutics (PHXM), iBio (IBIO), Sensei Biotherapeutics (SNSE), BioCardia (BCDA), IM Cannabis (IMCC), BioVie (BIVI), Biofrontera (BFRI), TransCode Therapeutics (RNAZ), Ainos (AIMD), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors PHAXIAM Therapeutics iBio Sensei Biotherapeutics BioCardia IM Cannabis BioVie Biofrontera TransCode Therapeutics Ainos X4 Pharmaceuticals PHAXIAM Therapeutics (NASDAQ:PHXM) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk. Do analysts prefer PHXM or PRFX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, PHXM or PRFX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM TherapeuticsN/AN/A-$240KN/AN/APainReformN/AN/A-$14.59M-$147.33-0.01 Does the media prefer PHXM or PRFX? In the previous week, PainReform had 5 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 5 mentions for PainReform and 0 mentions for PHAXIAM Therapeutics. PainReform's average media sentiment score of 0.47 beat PHAXIAM Therapeutics' score of 0.00 indicating that PainReform is being referred to more favorably in the news media. Company Overall Sentiment PHAXIAM Therapeutics Neutral PainReform Neutral Which has more volatility & risk, PHXM or PRFX? PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Do insiders & institutionals believe in PHXM or PRFX? 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is PHXM or PRFX more profitable? Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A PainReform N/A N/A N/A SummaryPainReform beats PHAXIAM Therapeutics on 5 of the 7 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.92M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-0.0122.0530.2925.74Price / SalesN/A742.42463.41115.83Price / CashN/A184.4138.2159.48Price / Book0.684.838.826.15Net Income-$14.59M$31.61M$3.25B$265.06M7 Day Performance6.77%4.55%3.70%2.60%1 Month Performance-4.70%5.69%5.84%2.83%1 Year Performance14.00%12.71%29.92%25.58% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform1.2708 of 5 stars$1.42-2.1%N/A+16.0%$2.92MN/A-0.014News CoverageUpcoming EarningsGap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049IBIOiBio1.1903 of 5 stars$0.63-0.7%$5.00+694.9%-63.4%$10.34M$375K0.00100Gap UpSNSESensei Biotherapeutics4.617 of 5 stars$8.20-5.2%$55.00+570.7%-41.8%$10.33MN/A-0.3640Gap DownBCDABioCardia3.675 of 5 stars$1.86-5.1%$25.00+1,244.1%-27.0%$10.23M$60K-0.8040Earnings ReportShort Interest ↓Gap DownIMCCIM Cannabis0.9563 of 5 stars$2.46-6.5%N/A-11.0%$9.95M$54.47M-3.84340News CoverageEarnings ReportShort Interest ↓Gap UpBIVIBioVie0.7754 of 5 stars$5.25-12.6%N/A-92.5%$9.94MN/A-0.0710Upcoming EarningsGap UpBFRIBiofrontera2.6576 of 5 stars$0.99-2.0%$2.75+179.2%-15.3%$9.94M$38.00M-0.4370News CoverageEarnings ReportGap UpRNAZTransCode Therapeutics1.9866 of 5 stars$11.49+0.7%$280.00+2,338.0%-99.8%$9.58MN/A0.009Earnings ReportShort Interest ↑Gap UpAIMDAinos0.9711 of 5 stars$2.26-8.5%N/A+5.3%$9.47M$20K-0.3540News CoverageEarnings ReportUpcoming EarningsShort Interest ↑XFORX4 Pharmaceuticals4.364 of 5 stars$1.61+1.6%$72.33+4,406.7%-82.9%$9.41M$2.56M0.7680Earnings ReportAnalyst ForecastShort Interest ↑Gap Down Related Companies and Tools Related Companies PHXM Competitors IBIO Competitors SNSE Competitors BCDA Competitors IMCC Competitors BIVI Competitors BFRI Competitors RNAZ Competitors AIMD Competitors XFOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access